Focus Health offers by the use of Dendritic Cells the fourth pillow in the modern cancer therapy:

Dendritic Cell Vaccination (DC vaccination) is a personalized activated immunotherapy.

By activating the patient’s own immune system we may achieve a major anti aging effect on healthy patients. The DC’s that are used for Dendritic Cell therapy are modified in the laboratory to strengthen their ability to activate the patient’s own immune system.

During our manufacturing process in a highly sterile clean room, we transfer the information about the personalized cancer antigen to a precursor cell. This then grows into a Dendritic Cell with this antigen knowledge. Each individual Dendritic Cell passes this information onto over 30,000 T-cells, which has an incredible effect on the immune system. When administered back to the patient these activated DC’s will eradicate all harmful cells and make also unidentified tumor cells disappear.

What makes our therapy special is a unique feature that no other provider has: in the process of the transformation of the precursor cell into a Dendritic Cell, the messenger substance interleukin10 is normally simultaneously produced. This messenger substance has the disadvantage that it can inhibit the effectiveness of DC’s and even it came rarely to strong immune reactions. In our procedure, no interleukin 10 is produced - instead, INTERLEUKIN 12 is produced in a dose that is up to 8 times higher. Interleukin 12 on the other hand, is a messenger substance that enables the Natural Killer cells to penetrate the cancer cells much more easily. For this reason, we also refer to our therapeutic approach as "Double Action".

The DC’s are injected subcutaneously like a vaccination. Occasionally, DC’s are also injected into a lymph node. Duration of treatment mainly depends on how the patient responds to this particular treatment and if the cancer is strongly mutating. With the help of DC’s a cancer patient’s immune system is activated in order to stimulate anti-tumor immunity and to bypass tumor-induced immunosuppression. It is claimed and rationalized that DC-induced activation of the patient’s own immune system could result in eradication of tumor cells and shrinkage or clearance of the tumor.

More than 2’000 clinical trials have been performed using DC’s as adjuvants in cancer therapy (melanoma, prostate cancer, renal cell carcinoma, brain tumors, hematological cancers, breast cancer, colorectal cancer, liver cancer, lung cancer, pancreas cancer and thyroid cancer amongst others). The FDA already approved a DC based drug (Sipuleucel-T) in the US for use against prostate cancer.

Administration of DC-based vaccines proved to be well tolerated. As we work with the patient's own blood, an allergic reaction in the form of anaphylactic shock is not possible. Moreover, increasing evidence suggests that DC vaccines could be used in a combinatorial approach with chemotherapy, after a cancer surgery or other treatment modalities.

Immunotherapy in the fight against cancer with Dendritic Cells is the state-of-the-art therapy, especially when offered with Focus Health's unique Double Action.